BOSTON — Crinecerfont, an investigational oral selective corticotropin-releasing factor type 1 receptor antagonist, benefits both adults and children with congenital adrenal hyperplasia (CAH) due to ...

SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a classic congenital adrenal hyperplasia (CAH)-focused supplement in The Journal of ...

Higher glucocorticoid doses for adults with congenital adrenal hyperplasia may be associated with lower bone mineral density, especially among women and those prescribed prednisolone, according to ...

Credit: Shutterstock. Crinecerfort is an investigational, oral, selective corticotropin-releasing factor type 1 receptor (CRF1) antagonist. A phase 3 study evaluating the efficacy and safety of ...

Adrenal hormone function was restored in animal studies, potentially paving the way for a functional cure for primary adrenal insufficiency in humans, according to research presented by Aspect ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved crinecerfont to treat patients with congenital adrenal hyperplasia. The drug directly reduces ...

(RTTNews) - BridgeBio Pharma Inc. (BBIO) said that the U.S. Food and Drug Administration granted Fast Track designation to BBP-631, an investigational adeno-associated virus 5 gene therapy designed ...

People with classic congenital adrenal hyperplasia (CAH) may suffer from impaired bone health, largely due to standard treatments. Most often caused by a genetic mutation in the 21-hydroxylase enzyme, ...

Crenessity is expected to be available commercially in approximately 1 week through PANTHERx Rare, a specialty pharmacy. The Food and Drug Administration (FDA) has approved Crenessity TM (crinecerfont ...

Congenital adrenal hyperplasia (CAH) is a disorder that affects the adrenal gland's ability to release hormones that regulate the body's response to stress and illness. CAH is treatable, but can be ...